Yves De Repentigny
Overview
Explore the profile of Yves De Repentigny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Almeida M, De Repentigny Y, Gagnon S, Sutton E, Kothary R
Elife
. 2025 Feb;
13.
PMID: 39976226
Spinal muscular atrophy (SMA) is caused by mutations in the Survival Motor Neuron 1 () gene. While traditionally viewed as a motor neuron disorder, there is involvement of various peripheral...
2.
Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy
Mikhail A, Ng S, Xhuti D, Lesinski M, Chhor J, Deguise M, et al.
J Cachexia Sarcopenia Muscle
. 2025 Feb;
16(1):e13701.
PMID: 39901351
Background: Spinal muscular atrophy (SMA) is a health- and life-limiting neuromuscular disorder. Although varying degrees of mitochondrial abnormalities have been documented in SMA skeletal muscle, the influence of disease progression...
3.
Gurriaran-Rodriguez U, Datzkiw D, Radusky L, Esper M, Javandoost E, Xiao F, et al.
Sci Adv
. 2024 Dec;
10(50):eado5914.
PMID: 39661666
Wnt proteins are hydrophobic glycoproteins that are nevertheless capable of long-range signaling. We found that Wnt7a is secreted long distance on the surface of extracellular vesicles (EVs) following muscle injury....
4.
Sutton E, Beauvais A, Yaworski R, De Repentigny Y, Reilly A, de Almeida M, et al.
EBioMedicine
. 2024 Nov;
110:105444.
PMID: 39515026
Background: The liver is a key metabolic organ, acting as a hub to metabolically connect various tissues. Spinal muscular atrophy (SMA) is a neuromuscular disorder whereby patients have an increased...
5.
Liu H, Chehade L, Deguise M, De Repentigny Y, Kothary R
Hum Mol Genet
. 2024 Nov;
34(1):21-31.
PMID: 39505369
Spinal muscular atrophy (SMA) is characterized by low levels of the ubiquitously expressed Survival Motor Neuron (SMN) protein, leading to progressive muscle weakness and atrophy. Skeletal muscle satellite cells play...
6.
Gurriaran-Rodriguez U, De Repentigny Y, Kothary R, Rudnicki M
Skelet Muscle
. 2024 Oct;
14(1):22.
PMID: 39394606
We have recently made the strikingly discovery that upon a muscle injury, Wnt7a is upregulated and secreted from new regenerating myofibers on the surface of exosomes to elicit its myogenerative...
7.
Kornfeld S, Cummings S, Yaworski R, De Repentigny Y, Gagnon S, Zandee S, et al.
Commun Biol
. 2024 Jul;
7(1):813.
PMID: 38965401
Strategies for treating progressive multiple sclerosis (MS) remain limited. Here, we found that miR-145-5p is overabundant uniquely in chronic lesion tissues from secondary progressive MS patients. We induced both acute...
8.
Gurriaran-Rodriguez U, Datzkiw D, Radusky L, Esper M, Xiao F, Ming H, et al.
bioRxiv
. 2023 Jul;
PMID: 37398399
Wnt proteins are secreted hydrophobic glycoproteins that act over long distances through poorly understood mechanisms. We discovered that Wnt7a is secreted on extracellular vesicles (EVs) following muscle injury. Structural analysis...
9.
Chehade L, Deguise M, De Repentigny Y, Yaworski R, Beauvais A, Gagnon S, et al.
Front Cell Neurosci
. 2022 Aug;
16:972029.
PMID: 35990890
Spinal muscular atrophy (SMA) is a monogenic neuromuscular disease caused by low levels of the Survival Motor Neuron (SMN) protein. Motor neuron degeneration is the central hallmark of the disease....
10.
Deguise M, Pileggi C, De Repentigny Y, Beauvais A, Tierney A, Chehade L, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Feb;
12(1):354-377.e3.
PMID: 33545428
Background & Aims: Nonalcoholic fatty liver disease (NAFLD) is considered a health epidemic with potential devastating effects on the patients and the healthcare systems. Current preclinical models of NAFLD are...